Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
fda
life sciences
national blog main
billy dunn
biogen
biotech ipos
boston
boston blog main
boston top stories
drug prices
drug pricing
dyne therapeutics
europe top stories
evrysdi
gene therapy
genentech
ionis pharmaceuticals
metacrine
myotonic dystrophy type 1
national
national top stories
new york top stories
nonalcoholic steatohepatitis
novartis
nusinersen
rare disease drugs
rare diseases
risdiplam
rna drugs
roche
salk institute
san diego blog main
san diego top stories
san francisco top stories
spinal muscular atrophy
spinraza
ulcerative colitis
zolgensma
What
drug
2
×
muscular
2
×
approved
atrophy
brings
company
daily
developing
disorders
dyne
dyne’s
evrysdi
fda
friday
genetic
green
home
intended
ipo
lights
liquid
medicine
medicines
million
muscle
new
oral
patients
preclinical
raised
rare
risdiplam
roche
spinal
stage
therapeutics
therapy
topped
upsized
Language
unset
Current search:
muscular
×
drug
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
